Bio-IT World August 28, 2024
Outpace Bio will advance multiple programmed T cell product candidates to early clinical proof-of-concept for the treatment of solid tumors; Foresight Diagnostics plans to accelerate the clinical development and commercialization of their cancer recurrence testing platform, PhasED-Seq; PreciseDx plan to expand commercialization efforts for PreciseBreast risk assessment, an AI-Powered test used to assess early-stage invasive breast cancer risk; and more.
$600M: Fund for Biotech, Medical Devices, Synthetic Biology, Diagnostics Companies
Symbiotic Capital was officially unveiled with more than $600 million in capital committed and targeted for investments and co-investments. Symbiotic will structure and originate credit solutions to life science companies to support scientific innovation across biotechnology, medical devices, diagnostics, tools, synthetic biology, and other healthcare...
Today's Sponsors
Today's Sponsor